Ciclesonide Responsive Allergic Rhinitis Therapeutics
1. Omnaris patent expiration
Treatment: Nasal treatment of seasonal and perennial allergic rhinitis symptoms; Treatment of nasal symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older. treatment ...
OMNARIS's oppositions filed in EPO
OMNARIS IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5482934 | COVIS | Pregna-1,4-diene3,20-dione-16-17-acetal-21 esters, process for their preparation, composition, and methods for the treatment of inflammatory conditions |
Oct, 2017
(8 years ago) | |
| US7235247 | COVIS | Pharmaceutical composition for application to mucosa |
Apr, 2019
(6 years ago) | |
| US6767901 | COVIS | Ciclesonide contained pharmaceutical composition for application to mucosa |
Oct, 2020
(5 years ago) | |
| US6939559 | COVIS | Pharmaceutical composition for application to mucosa |
Apr, 2019
(6 years ago) | |
| US8383611 | COVIS | Ciclesonide containing aqueous pharmaceutical composition |
Oct, 2020
(5 years ago) | |
| US8371292 | COVIS | Use of ciclesonide for the treatment of respiratory diseases |
Feb, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 20, 2011 |
Drugs and Companies using CICLESONIDE ingredient
NCE-1 date: 20 October, 2010
Market Authorisation Date: 20 October, 2006
Dosage: SPRAY, METERED
How can I launch a generic of OMNARIS before it's drug patent expiration?
More Information on Dosage
OMNARIS family patents
